Alterity Therapeutics price target raised to $12 from $8 at Maxim

Maxim analyst Jason McCarthy raised the firm’s price target on Alterity Therapeutics (ATHE) to $12 from $8 and keeps a Buy rating on the shares after the company reported Phase 2 data for lead asset ATH434 in patients with early-stage multiple system atrophy. The data are “mixed but overall positive,” says the analyst, who adds that the relatively small trial should inform the design of a later-stage study.